Patents by Inventor Jon SHEPHERD

Jon SHEPHERD has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF METTL3
    Publication number: 20240101589
    Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: W—X—Y—Z (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.
    Type: Application
    Filed: October 7, 2021
    Publication date: March 28, 2024
    Inventors: DAVID JAMES HARDICK, Wesley Peter Blackaby, Elizabeth Jane Thomas, Frederick Arthur Brookfield, Jon Shepherd, Christian Bubert, Mark Peter Ridgill
  • METTL3 INHIBITORY COMPOUNDS
    Publication number: 20230391770
    Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X—Y—Z (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.
    Type: Application
    Filed: October 5, 2021
    Publication date: December 7, 2023
    Inventors: David James Hardick, Wesley Peter Blackaby, Elizabeth Jane Thomas, Frederick Arthur Brookfield, Jon Shepherd, Christian Bubert, Mark Peter Ridgill
  • Polyheterocyclic compounds as METTL3 inhibitors
    Patent number: 11725010
    Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X—Y—Z??(I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: August 15, 2023
    Assignee: Storm Therapeutics Limited
    Inventors: Wesley Peter Blackaby, Elizabeth Jane Thomas, David James Hardick, Jon Shepherd, Frederick Arthur Brookfield, Christian Bubert, Mark Peter Ridgill
  • POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS
    Publication number: 20230116403
    Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X—Y—Z??(I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.
    Type: Application
    Filed: December 1, 2020
    Publication date: April 13, 2023
    Inventors: Wesley P. Blackaby, Ekizabeth Jane Thomas, David james Hardick, Jon Shepherd, Frederick Arthur Brookfield, Christian Bubert, Mark Peter Ridgill
  • METTL3 INHIBITORY COMPOUNDS
    Publication number: 20230085408
    Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X—Y—Z5 (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity 10 is implicated.
    Type: Application
    Filed: April 3, 2020
    Publication date: March 16, 2023
    Inventors: Wesley Peter BLACKABY, David James HARDICK, Elizabeth Jane THOMAS, Frederick Arthur BROOKFIELD, Christian BUBERT, Jon SHEPHERD, Mark Peter RIDGILL
  • POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS
    Publication number: 20230002378
    Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X—Y—Z??(I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.
    Type: Application
    Filed: July 29, 2022
    Publication date: January 5, 2023
    Inventors: Wesley Peter Blackaby, Elizabeth Jane Thomas, David James Hardick, Jon Shepherd, Frederick Arthur Brookfield, Christian Bubert, Mark Peter Ridgill
  • Novel Ferroportin Inhibitors
    Publication number: 20220363675
    Abstract: The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
    Type: Application
    Filed: June 7, 2021
    Publication date: November 17, 2022
    Inventors: Franz Dürrenberger, Michael Burgert, Susanna Burckhardt, Wilm Buhr, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
  • Antiviral compounds
    Patent number: 11180479
    Abstract: The present invention relates to novel compounds of general formula (I) wherein R1 to R4 and n have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: November 23, 2021
    Assignee: HAPLOGEN GMBH
    Inventors: Wolfgang Fischl, Christopher John Yarnold, Patricia Leonie Amouzegh, Kevin Thewlis, Jon Shepherd, Mark Anthony Kerry
  • Ferroportin inhibitors
    Patent number: 11066399
    Abstract: The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: July 20, 2021
    Assignee: Vifor (International) AG
    Inventors: Franz Dürrenberger, Michael Burgert, Susanna Burckhardt, Wilm Buhr, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
  • Ferroportin inhibitors
    Patent number: 11001579
    Abstract: The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: May 11, 2021
    Assignee: Vifor (International) AG
    Inventors: Franz Dürrenberger, Michael Burgert, Susanna Burckhardt, Wilm Buhr, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
  • Ferroportin inhibitors
    Patent number: 10738041
    Abstract: The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: August 11, 2020
    Assignee: Vifor (International) AG
    Inventors: Franz Dürrenberger, Wilm Buhr, Susanna Burckhardt, Michael Burgert, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
  • ANTIVIRAL COMPOUNDS
    Publication number: 20200239446
    Abstract: The present invention relates to novel compounds of general formula (I) wherein R1 to R4 and n have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.
    Type: Application
    Filed: October 5, 2018
    Publication date: July 30, 2020
    Inventors: Wolfgang FISCHL, Christopher John YARNOLD, Patricia Leonie AMOUZEGH, Kevin THEWLIS, Jon SHEPHERD, Mark Anthony KERRY
  • Novel Ferroportin Inhibitors
    Publication number: 20190345151
    Abstract: The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
    Type: Application
    Filed: June 12, 2019
    Publication date: November 14, 2019
    Inventors: Franz Dürrenberger, Michael Burgert, Susanna Burckhardt, Wilm Buhr, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
  • Ferroportin inhibitors
    Patent number: 10364239
    Abstract: The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: July 30, 2019
    Assignee: Vifor (International) AG
    Inventors: Franz Dürrenberger, Michael Burgert, Susanna Burckhardt, Wilm Buhr, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
  • Novel Ferroportin Inhibitors
    Publication number: 20180319783
    Abstract: The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
    Type: Application
    Filed: October 21, 2016
    Publication date: November 8, 2018
    Inventors: Franz Dürrenberger, Michael Burgert, Susanna Burckhardt, Wilm Buhr, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
  • Novel Ferroportin Inhibitors
    Publication number: 20180297991
    Abstract: The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
    Type: Application
    Filed: October 21, 2016
    Publication date: October 18, 2018
    Inventors: Franz Dürrenberger, Wilm Buhr, Susanna Burckhardt, Michael Burgert, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
  • Tricyclic compounds for inhibiting the CFTR channel
    Patent number: 9359381
    Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: June 7, 2016
    Assignee: Novartis AG
    Inventors: Mahbub Ahmed, Alexander Ashall-Kelly, Louisa Gueritz, Jeffrey McKenna, Joseph McKenna, Simon Mutton, Rakesh Parmar, Jon Shepherd, Paul Wright
  • TRICYCLIC COMPOUNDS FOR INHIBITING THE CFTR CHANNEL
    Publication number: 20150336986
    Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: December 17, 2013
    Publication date: November 26, 2015
    Applicant: Novartis AG
    Inventors: Mahbub AHMED, Alexander ASHALL-KELLY, Louisa GUERITZ, Jeffrey MCKENNA, Joseph MCKENNA, Simon MUTTON, Rakesh PARMAR, Jon SHEPHERD, Paul WRIGHT
  • TRICYCLIC COMPOUNDS
    Publication number: 20140171417
    Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: December 17, 2013
    Publication date: June 19, 2014
    Applicant: NOVARTIS AG
    Inventors: Mahbub AHMED, Alexander ASHALL-KELLY, Louisa GUERITZ, Jeffrey MCKENNA, Joseph MCKENNA, Simon MUTTON, Rakesh PARMAR, Jon SHEPHERD, Paul WRIGHT